Showing 5231-5240 of 7750 results for "".
- Suneva Medical Completes Initial Treatment in Phase 3 Acne Scar Studyhttps://practicaldermatology.com/news/20121024-suneva_medical_completes_initial_treatment_in_phase_3_acne_scar_study/2459695/Suneva Medical, Inc. announced that it has completed the enrollment and initial treatment of patients in its Phase 3 acne scar study. This multi-center, prospective study is investigating the efficacy of Artefill for the treatment of moderate to
- Nuvo and Galderma Win FDA Approval for Topical Peelhttps://practicaldermatology.com/news/20121022-nuvo_and_galderma_win_fda_approval_for_topical_peel/2459699/Nuvo Research announced that the FDA has approved its Pliaglis product, a topical anesthetic cream designed to minimize pain during aesthetic dermatological procedures such as dermal filler injection, pulsed dye laser therapy, facial laser resurfacing, and laser-assisted tattoo removal. The approval
- TURO SKIN System Launchedhttps://practicaldermatology.com/news/20121018-turo_skin_system_launched/2459701/Founder and CEO John Renucci, MD, created TURO SKIN, a simplified skincare system for men, which has now been released. The collection offers solutions for face, shave, hair, and body. TURO SKIN products are available online at www.turoskin.com an
- New Fractionated Skin Resurfacing Module Enhances RF Laser Treatmentshttps://practicaldermatology.com/news/20121017-new_fractionated_skin_resurfacing_module_shortens_rf_laser_treatments/2459704/The PixelRF fractionated skin resurfacing module from Alma Lasers, Inc. uses proprietary InMotion Refractive Radiofrequency Micro Plasma Technology, which both ablates and heats the skin through controlled, focused delivery of energy without using disposables. The PixelRF was recently added to Alma'
- Revance Regains Rights to Its Botulinum Toxinshttps://practicaldermatology.com/news/20121009-revance_regains_rights_to_its_botulinum_toxins/2459713/Revance Therapeutics, Inc. announced a settlement and termination agreement for its contractual relationships with Medicis Pharmaceutical Corporation concerning RT001 Botulinum Toxin Type A Topical Gel and RT002 Injectable Botulinum Toxin Type A.
- Pharma Penalties Total $10.2B Over Two Yearshttps://practicaldermatology.com/news/20120928-pharma_penalties_total_102b_over_two_years/2459727/Pharmaceutical manufacturers have reached a total of 74 settlements, totaling $10.2 billion in financial penalties with federal and state governments between November 2, 2010 and July 18, 2012. That's the conclusion of an updated report from P
- Skin Tightening Induced by Fractional CO2 Laserhttps://practicaldermatology.com/news/20120918-skin_tightening_induced_by_fractional_co2_laser/2459735/Variations in mechanical properties of treated skin confirm skin tightening after CO2 fractional resurfacing laser treatment. (J Cosmet Dermatol; 11(3):201-6) Researchers measured dermal elasticity using suction applied with an in vivo skin elasticity meter (Cutometer). Significant improvement was s
- Humira Talking Pen Launched to Educate on Self-injectionhttps://practicaldermatology.com/news/20120917-humira_talking_pen_launched_to_educate_on_self-injection/2459737/Abbott Laboratories, makers of Humira, released the Humira Talking Training Pen, available at no cost as part of the myHUMIRA patient support program (humira.com/m
- CMS Provider Call Today on EHRshttps://practicaldermatology.com/news/20120913-cms_provider_call_today_on_ehrs/2459740/The Centers for Medicare and Medicaid Services will host a 90-minute National Provider Call today, Sept. 13, to discuss the final rule for the Stage 2 electronic health records meaningful use program. The call is free, but prior registration is required.
- Neodyne Biosciences Announces Positive Interim Trial Results for Embracehttps://practicaldermatology.com/news/20120807-neodyne_biosciences_announces_positive_interim_trial_results_for_embrace/2459756/Neodyne Biosciences, Inc. announced positive interim results from the REFINE Trial (Scar Prevention and the Clinical Effectiveness of a Novel Mechano-modulating Polymer), a randomized, control clinical trial designed to assess the efficacy and